Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer.

ABSTRACT: Interventions: Alternate-day S-1 (80mg/m2; day 2,4,6...14) combined with irinotecan (150mg/m2; day 1) and bevacizumab (5.0 mg/kg; day 1) Primary outcome(s): Incidence of grade 3 or 4 diarrhea Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2624349 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)

Project description:Interventions: Irinotecan 150 mg/m2/biweekly div l-LV 200mg/m2/biweekly div 5-FU/bolus 400mg/m2/biweekly div (bolus) 5-FU/infusional 2,400mg/m2/biweekly div Panitumumab 6mg/kg/biweekly div or S-1 80mg/m2/day p.o. day 1-7 Irinotecan 150mg/m2 day 1 Panitumumab 6mg/kg/biweekly div Irinotecan 150mg/m2/ biweekly div Panitumumab 6mg/kg/biweekly div Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

| 2623074 | ecrin-mdr-crc

Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer

Project description:Interventions: S-1 : day1-14 80mg/m2. CPT-11 : day1 150mg/m2 Cetuximab : day1,8,15 400mg/m2 (1st time) , 250mg/m2 (2nd time or another) to be repeated every 3 weeks Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2622216 | ecrin-mdr-crc

A phase I/II study of S-1+Irinotecan+panitumumab as first line treatment to advanced colorectal cancer

Project description:Interventions: S-1 80mg/m2 Oral administration day1-15 Irinotacan 150mg/m2 90min div day 1 Panitumumab 9mg/m2 90-30min div day 1 A single course to three weeks. Primary outcome(s): phase I: Estimated percentage of dose-limiting toxicity at first course. phase II: Response rate Study Design: Single arm Non-randomized

| 2620774 | ecrin-mdr-crc

Randomized phase II trial of Hange-shasin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS+Bev second-line treatment

Project description:Interventions: S-1+CPT-11+bevacizumab+Placebo S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Placebo day1-28 q4w S-1+CPT-11+bevacizumab+hange-shashin-to S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Hange-shashin-to 7.5g/day day1-28 q4w Primary outcome(s): Incidence of grade 3 or more diarrhea until the end of 3rd cycle Study Design: Parallel Randomized

| 2627635 | ecrin-mdr-crc

Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2623833 | ecrin-mdr-crc

Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.

Project description:Interventions: CPT-11 150mg/m2 i.v. (day1) Bev 7.5mg/kg i.v. (day1) S-1 80mg/m2 p.o. (day1-14) to be repeated every 3 weeks Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2621739 | ecrin-mdr-crc

Expression data from Day 15 bovine conceptuses

Project description:The majority of pregnancy loss in cattle occurs between days 8 and 16 of gestation coincident with the initiation of conceptus elongation and the onset of maternal recognition of pregnancy. Differences in conceptus lengths on the same day of gestation may be related to an inherent lack of developmental competency or may simply be a consequence of asynchrony with the maternal environment. The primary objective of this work was to characterize differential patterns of mRNA expression between short and long bovine conceptuses recovered on Day 15 of gestation. Embryo selection is an important factor that contributes to pregnancy success following transfer of embryos produced in vivo or in vitro. Morphological evaluation of embryos for stage of development and quality grade is the most widely used method for predicting embryo viability in cattle. Multiple studies have demonstrated that there are significant differences in pregnancy rates across different morphological grades. However, morphological evaluation is not always the best predictor of pregnancy success. Therefore, it is of interest to develop an objective and highly predictive method of pre-transfer embryo screening. A secondary objective of this experiment was to characterize differential patterns of mRNA expression between Day 15 bovine conceptuses derived from Grade 1 (excellent) and Grade 3 (poor) embryos. In Experiment 1, gene expression was compared between Day 15 conceptuses derived from the transfer of Grade 1 (n=4) versus Grade 3 (n=3) embryos. In Experiment 2, gene expression was compared between Grade 1-derived Day 15 conceptuses classified as either short (n=5) or long (n=5) in length.

2015-12-08 | E-GEOD-75750 | biostudies-arrayexpress

A Phase II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy

Project description:Interventions: XELIRI plus bevacizumab therapy Capecitabine: 2000 mg/m2 day1 to 8 CPT11 150mg/m2 day1 Bevacizumab: 10mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity. Primary outcome(s): progression free survival and safety Study Design: Single arm Non-randomized

| 2624679 | ecrin-mdr-crc

A phase I study of alternate-day administration of S-1 plus leucovorin with bevacizumab in patients with refractory metastatic colorectal cancer.

Project description:Interventions: alternate-day administration of S-1 plus leucovorin with bevacizumab Primary outcome(s): recommended dose Study Design: Single arm Non-randomized

| 2631419 | ecrin-mdr-crc

Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapy

Project description:Interventions: TS-1+Irinotecan+Bevacizumab therapy Bevacizumab 7.5mg/m2/tri-weekly Irinotecan 150mg/m2/tri-weekly TS-1 80-120mg/day, for 14 days followed by 1 week rest Primary outcome(s): 6-Month Progression Free Survival Rate Study Design: Single arm Non-randomized

| 2625708 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data